THERAFLU WARMING RELIEF NIGHTTIME SEVERE COLD & COUGH OTC
Generic Name and Formulations:
Acetaminophen 325mg, diphenhydramine HCl 12.5mg, phenylephrine HCl 5mg; per 15mL; soln; contains alcohol 10%; contains potassium 5mg/15mL, sodium 7mg/15mL; cherry flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF NIGHTTIME SEVERE COLD & COUGH:
Minor aches and pains. Headache. Fever. Sneezing. Rhinorrhea. Nasal and sinus congestion. Itchy eyes, nose, throat.
30mL every 4 hours as needed. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen, diphenhydramine (including skin) products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. COPD. Asthma. GI or GU obstuction. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + sympathomimetic.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis